Herpes Simplex News and Research

RSS

Herpes simplex is a viral disease caused by herpes simplex viruses; both herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) cause herpes simplex. Infection with the herpes virus is categorized into one of several distinct disorders based on the site of infection.

Chimerix to present CMX001 data for viral infections at IDSA Annual Meeting

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, will present promising clinical data for CMX001 in a late-breaker poster session at the Infectious Diseases Society of America (IDSA) 48th Annual Meeting.

25 Oct 2010

NanoViricides' President delivers speech at ASNM Second Annual Conference

NanoViricides, Inc. announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM).

18 Oct 2010

NanoViricides files financial year end annual report with SEC

NanoViricides, Inc. reports that it has filed its financial year end annual report (Form 10K) with the Securities and Exchange Commission (SEC) yesterday in a timely manner.

14 Oct 2010

HSV1716 clinical trial for childhood cancer receives FDA grant

A clinical trial testing a genetically reprogrammed herpes simplex virus as treatment for deadly forms of childhood cancer has received a U.S. Food and Drug Administration grant to support the research.

13 Oct 2010

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN and Abbott today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

From Qiagen 13 Oct 2010

Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease

An experimental vaccine intended to prevent genital herpes disease in women, although generally safe and well-tolerated, proved ineffective when tested in the recently concluded clinical study known as the Herpevac Trial for Women.

1 Oct 2010

Condoms can prevent transmission of herpes simplex virus 2: Study

Condom use is associated with a reduced risk of contracting herpes simplex virus 2, according to a report based on pooled analysis of data from previous studies in the July 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Sep 2010

FDA approves OZURDEX implant for uveitis treatment

Allergan, Inc. today announced that the United States Food and Drug Administration (FDA) has approved OZURDEX (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye.

27 Sep 2010

Raltegravir could be valid target against all Herpesviridae

Scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by the coordinator of the Structural and Computational Biology Programme, Miquel Coll, have published a new study that demonstrates that raltegravir, the drug approved in 2007 for the treatment of AIDS that is sold by Merck under the name Isentress, cancels the function of an essential protein for the replication of one kind of herpes virus.

23 Sep 2010

Study: No association between first-trimester exposure to antiherpetic antiviral drugs and major birth defects

An analysis of data from Denmark finds no associated increased risk of major birth defects for mothers who were exposed during the first trimester of pregnancy to the antiviral drugs acyclovir, valacyclovir, and famciclovir, often used to treat herpes simplex and herpes zoster infections, according to a study in the August 25 issue of JAMA.

25 Aug 2010

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

NanoViricides, Inc., reports that its anti-Herpes drug candidates demonstrated significant efficacy in the recently completed cell culture studies. The studies were performed in the laboratory of Dr. Ken Rosenthal at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

16 Aug 2010

NanoBio Corporation receives U.S. patent for nanoemulsion technology

NanoBio Corporation announced today that it has been awarded a seventh U.S. patent covering its novel nanoemulsion technology. The new claims encompass methods of treating Herpes Simplex I infections, including herpes labialis (commonly referred to as cold sores), using NanoBio's proprietary anti-infective nanoemulsion product candidates.

5 Aug 2010

Vical second-quarter revenues decrease to $2.1 million

Vical Incorporated today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co., Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine.

3 Aug 2010

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

DIATHERIX Laboratories ,adds a Sexually Transmitted Disease (STD) panel and Herpes Simplex Virus (HSV) panel to its line up of highly sensitive, rapid response diagnostic panels. The HSV panel identifies herpes simplex viruses 1 and 2 and the STD panel identifies 10 sexually transmitted diseases simultaneously, many of which cannot be accurately identified by current testing methods. These STD organisms, if not appropriately treated, can cause diseases such as syphilis, gonorrhoeae, chlamydia, bacterial vaginosis, etc. and may lead to blindness, infertility or complications during pregnancy.

28 Jul 2010

Antigenics announces positive results of AG-707 genital herpes vaccine

Antigenics announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2,the virus that causes genital herpes, in infected patients. Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells.

28 Jul 2010

Scientists discover mechanism of herpes virus cell entry machinery

The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.

27 Jul 2010

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Vical Incorporated today announced that its prophylactic Vaxfectin®-formulated plasmid DNA (pDNA) vaccine against herpes simplex virus type 2 (HSV-2) protected mice against lethal challenge, provided sterilizing immunity and inhibited viral counts at both the primary and latent infection sites. The Vaxfectin® adjuvant substantially improved vaccine effectiveness. A related vaccine significantly reduced the recurrence of HSV-2 lesions in a therapeutic model using guinea pigs with latent infection.

26 Jul 2010

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman's risk of being infected with these viruses. The results of the ground-breaking safety and effectiveness study of an antiretroviral microbicide gel study were reported today by the Centre for the AIDS Programme of Research in South Africa at the XVIII International AIDS Conference in Vienna, Austria.

20 Jul 2010

Fatness drives inactivity, not the other way around

According to a recent longitudinal study in children, inactivity does not lead to fatness! Moreover, the authors concluded that fatness is driving inactivity, and not the other way around. The authors noted that this "reverse causality" explains the observed association between inactivity and fatness. It also explains the repeated failures of the attempts to reduce childhood obesity by increasing physical activity. The study was published in the Archives of Disease in Childhood by Dr. Brad Metcalf and colleagues from Plymouth, UK.

15 Jul 2010

Scientists shrink distant sarcomas with genetically reprogrammed herpes virus and anti-vascular drug

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice – still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy.

8 Jul 2010